Search Within

Sergio Andres Giralt

Formats
  1. Meeting Abstract (632)
  2. Journal Article (373)
  3. Research Letter (18)
  4. Review (15)
  5. Guidelines (5)
  6. Editorial (4)
  7. Book Section (3)
  8. Correspondence (3)
Groups
  1. Bone Marrow Transplant (1053)
  2. Center for Hematologic Malignancies (1053)
  3. Department of Medicine (1053)
  4. Hematologic Malignancies, Division of (1053)
  5. Survivorship Research (687)
  6. CTCR Scholars (542)

More Groups

People
  1. Miguel-Angel Perales (423)
  2. Sean Devlin (373)
  3. Gunjan Shah (299)
  4. Michael Scordo (268)
  5. Heather Landau (253)
  6. Ann Jakubowski (240)

More People

Years
  1. 2025 (12)
  2. 2024 (55)
  3. 2023 (104)
  4. 2022 (77)
  5. 2021 (66)
  6. 2020 (91)

More Years

Publications
  1. Blood (304)
  2. Biology of Blood and Marrow Transplantation (275)
  3. Bone Marrow Transplantation (80)
  4. Clinical Lymphoma, Myeloma and Leukemia (60)
  5. Journal of Clinical Oncology (40)
  6. Transplantation and Cellular Therapy (36)

More Publications

Publishers
  1. Elsevier Inc. (384)
  2. American Society of Hematology (337)
  3. Nature Publishing Group (108)
  4. American Society of Clinical Oncology (42)
  5. Taylor & Francis Group (35)
  6. Ferrata Storti Foundation (13)

More Publishers

Results (1053)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transplantation and cellular therapy for older adults—The MSK approach
    Review

    Lin, R. J.; Dahi, P. B.; Korc-Grodzicki, B.; Shahrokni, A.; Jakubowski, A. A.; Giralt, S. A.
    Current Hematologic Malignancy Reports (2024)

    Fulltext@MSK | Save
  • Optimizing high dose melphalan
    Review

    Shah, G.; Giralt, S.; Dahi, P.
    Blood Reviews (2024)

    Fulltext@MSK | Save
  • Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease
    Journal Article

    Lindner, S.; Miltiadous, O.; Ramos, R. J. F.; Paredes, J.; Kousa, A. I.; Dai, A.; Fei, T.; Lauder, E.; Frame, J.; Waters, N. R.; more...
    Nature Microbiology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
    Journal Article

    Metheny, L. L.; Sobecks, R.; Cho, C.; Fu, P.; Margevicius, S.; Wang, J.; Ciarrone, L.; Kopp, S.; Convents, R. D.; Majhail, N.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy
    Journal Article

    Infante, M. S.; Nemirovsky, D.; Devlin, S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Chung, D. J.; Politikos, I.; Barker, J.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Reduced-intensity compared to nonmyeloablative conditioning in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic stem cell transplantation
    Journal Article

    Nath, K.; Peterson, K.; Brown, S.; Devlin, S.; Rodriguez, N.; Barker, J.; Giralt, S.; Gyurkocza, B.; Jakubowski, A.; Papadopoulos, E.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
    Meeting Abstract

    Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Analysis of cytopenias and infections in pts from KarMMa-3
    Meeting Abstract

    Baz, R.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Nooka, A. K.; Costa, L.; Raje, N. S.; Abrahamsen, I. W.; Delforge, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • High-dose targeted radiation with (131)I-apamistamab prior to HCT demonstrated a dose-response for durable complete remission in patients with R/R AML
    Meeting Abstract

    Litzow, M. R.; Chen, G.; Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Abboud, C. N.; Koshy, N.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save